Actelion Zavesca AWP
Executive Summary
Actelion/Celltech's oral Gaucher disease therapy Zavesca (miglustat) is priced at an AWP of $9,337 for a 30-day supply of 90 capsules. Zavesca was approved as second-line therapy to Genzyme's Cerezyme (imiglucerase) in July (1"The Pink Sheet" Aug. 4, 2003, p. 37). CuraScript has been selected as Zavesca's exclusive pharmacy distributor...
You may also be interested in...
Actelion Zavesca Clears FDA; Available For Gaucher Patients By Year-End
Actelion/Celltech's Zavesca will be available to Gaucher disease patients before the end of the year following FDA approval of the drug July 31
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.